company background image
5407

Shree Ganesh Remedies BSE:540737 Stock Report

Last Price

₹244.65

Market Cap

₹2.9b

7D

3.2%

1Y

-28.7%

Updated

05 Oct, 2022

Data

Company Financials
540737 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance5/6
Financial Health6/6
Dividends1/6

540737 Stock Overview

Shree Ganesh Remedies Limited engages in the research, development, manufacture, and sale of pharmaceutical drug intermediates and fine chemicals for pharmaceutical industry in India.

Shree Ganesh Remedies Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Shree Ganesh Remedies
Historical stock prices
Current Share Price₹244.65
52 Week High₹429.55
52 Week Low₹220.00
Beta0.23
1 Month Change7.35%
3 Month Change-1.65%
1 Year Change-28.66%
3 Year Change381.55%
5 Year Changen/a
Change since IPO892.29%

Recent News & Updates

Shareholder Returns

540737IN PharmaceuticalsIN Market
7D3.2%5.0%1.4%
1Y-28.7%-11.3%-1.7%

Return vs Industry: 540737 underperformed the Indian Pharmaceuticals industry which returned -11.3% over the past year.

Return vs Market: 540737 underperformed the Indian Market which returned -1.7% over the past year.

Price Volatility

Is 540737's price volatile compared to industry and market?
540737 volatility
540737 Average Weekly Movement5.1%
Pharmaceuticals Industry Average Movement5.1%
Market Average Movement5.9%
10% most volatile stocks in IN Market9.2%
10% least volatile stocks in IN Market3.8%

Stable Share Price: 540737 is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 540737's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199597Chandulal Kothiahttps://www.ganeshremedies.com

Shree Ganesh Remedies Limited engages in the research, development, manufacture, and sale of pharmaceutical drug intermediates and fine chemicals for pharmaceutical industry in India. Its pharmaceutical drug intermediates comprise anti-arrhythmic, anti-cancer, anti-depressant, anti-diabetic, anti-diarrheal, anti-fungal, anti-histamine, anti-inflammatory, anti-parasitic, anti-psychotic, anticholinergic, birth-control, cardiovascular, gastrointestinal, neurological disorder, ophthalmic, opioid, and veterinary pharmaceutical ingredient intermediates. The company also offers fine and specialty chemicals, such as agro-chemicals, electronics, flavor and fragrance, life-sciences, and polymer chemicals, as well as other specialty chemicals, including hexamethylendichloride, octamethylendiamine, and suberonitrile for pharmaceutical, agricultural, and chemical applications.

Shree Ganesh Remedies Fundamentals Summary

How do Shree Ganesh Remedies's earnings and revenue compare to its market cap?
540737 fundamental statistics
Market Cap₹2.94b
Earnings (TTM)₹139.28m
Revenue (TTM)₹762.94m

21.1x

P/E Ratio

3.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
540737 income statement (TTM)
Revenue₹762.94m
Cost of Revenue₹397.88m
Gross Profit₹365.07m
Other Expenses₹225.79m
Earnings₹139.28m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)11.60
Gross Margin47.85%
Net Profit Margin18.26%
Debt/Equity Ratio0.0%

How did 540737 perform over the long term?

See historical performance and comparison

Dividends

0.2%

Current Dividend Yield

4%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is 540737 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 540737?

Other financial metrics that can be useful for relative valuation.

540737 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.8x
Enterprise Value/EBITDA15x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does 540737's PE Ratio compare to its peers?

540737 PE Ratio vs Peers
The above table shows the PE ratio for 540737 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average17.3x
540937 Medico Remedies
48.5xn/a₹2.5b
526953 Venus Remedies
7.8xn/a₹2.8b
500009 Ambalal Sarabhai Enterprises
10.3xn/a₹2.3b
524212 Wanbury
2.9xn/a₹2.1b
540737 Shree Ganesh Remedies
21.1xn/a₹2.9b

Price-To-Earnings vs Peers: 540737 is expensive based on its Price-To-Earnings Ratio (21.1x) compared to the peer average (17.3x).


Price to Earnings Ratio vs Industry

How does 540737's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

Price-To-Earnings vs Industry: 540737 is good value based on its Price-To-Earnings Ratio (21.1x) compared to the Indian Pharmaceuticals industry average (24.1x)


Price to Earnings Ratio vs Fair Ratio

What is 540737's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

540737 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio21.1x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 540737's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of 540737 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 540737 (₹244.65) is trading above our estimate of fair value (₹142.1)

Significantly Below Fair Value: 540737 is trading above our estimate of fair value.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Shree Ganesh Remedies forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


18.8%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Shree Ganesh Remedies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

Past Performance

How has Shree Ganesh Remedies performed over the past 5 years?

Past Performance Score

5/6

Past Performance Score 5/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


23.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 540737 has high quality earnings.

Growing Profit Margin: 540737's current net profit margins (18.3%) are lower than last year (19.7%).


Past Earnings Growth Analysis

Earnings Trend: 540737's earnings have grown significantly by 23% per year over the past 5 years.

Accelerating Growth: 540737's earnings growth over the past year (37.7%) exceeds its 5-year average (23% per year).

Earnings vs Industry: 540737 earnings growth over the past year (37.7%) exceeded the Pharmaceuticals industry -2.1%.


Return on Equity

High ROE: 540737's Return on Equity (22.6%) is considered high.


Discover strong past performing companies

Financial Health

How is Shree Ganesh Remedies's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 540737's short term assets (₹449.1M) exceed its short term liabilities (₹150.4M).

Long Term Liabilities: 540737's short term assets (₹449.1M) exceed its long term liabilities (₹4.0M).


Debt to Equity History and Analysis

Debt Level: 540737 is debt free.

Reducing Debt: 540737 has no debt compared to 5 years ago when its debt to equity ratio was 3%.

Debt Coverage: 540737 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 540737 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Shree Ganesh Remedies's current dividend yield, its reliability and sustainability?

Dividend Score

1/6

Dividend Score 1/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


0.20%

Current Dividend Yield

Dividend Yield vs Market

Shree Ganesh Remedies Dividend Yield vs Market
How does Shree Ganesh Remedies dividend yield compare to the market?
SegmentDividend Yield
Company (Shree Ganesh Remedies)0.2%
Market Bottom 25% (IN)0.4%
Market Top 25% (IN)1.6%
Industry Average (Pharmaceuticals)0.9%
Analyst forecast in 3 Years (Shree Ganesh Remedies)n/a

Notable Dividend: 540737's dividend (0.2%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.36%).

High Dividend: 540737's dividend (0.2%) is low compared to the top 25% of dividend payers in the Indian market (1.59%).


Stability and Growth of Payments

Stable Dividend: 540737 has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: 540737 has only been paying a dividend for 4 years, and since then payments have fallen.


Earnings Payout to Shareholders

Earnings Coverage: With its low payout ratio (4.3%), 540737's dividend payments are thoroughly covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: 540737 is paying a dividend but the company has no free cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average board tenure


CEO

Chandulal Kothia (59 yo)

27.5yrs

Tenure

₹9,900,000

Compensation

Mr. Chandulal Manubhai Kothia is Promoter, Chairman and Managing Director of Shree Ganesh Remedies Limited. Mr. Kothia has experience of more than two decades in the field of Manufacturing of pharmaceutica...


CEO Compensation Analysis

Chandulal Kothia's Compensation vs Shree Ganesh Remedies Earnings
How has Chandulal Kothia's remuneration changed compared to Shree Ganesh Remedies's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

₹139m

Mar 31 2022₹10m₹10m

₹134m

Dec 31 2021n/an/a

₹126m

Sep 30 2021n/an/a

₹112m

Jun 30 2021n/an/a

₹101m

Mar 31 2021₹6m₹6m

₹98m

Dec 31 2020n/an/a

₹94m

Sep 30 2020n/an/a

₹92m

Jun 30 2020n/an/a

₹99m

Mar 31 2020₹5m₹5m

₹105m

Dec 31 2019n/an/a

₹95m

Sep 30 2019n/an/a

₹86m

Jun 30 2019n/an/a

₹74m

Mar 31 2019₹3m₹3m

₹62m

Dec 31 2018n/an/a

₹56m

Sep 30 2018n/an/a

₹49m

Jun 30 2018n/an/a

₹48m

Mar 31 2018₹5m₹5m

₹47m

Compensation vs Market: Chandulal's total compensation ($USD121.66K) is above average for companies of similar size in the Indian market ($USD44.15K).

Compensation vs Earnings: Chandulal's compensation has increased by more than 20% in the past year.


Board Members

Experienced Board: 540737's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of 540737?
Owner TypeNumber of SharesOwnership Percentage
Private Companies102,3910.9%
General Public2,604,52621.7%
Individual Insiders9,299,81077.5%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 9 shareholders own 78.31% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
60.98%
Chandulal Kothia
7,321,876₹1.8b0%no data
8.3%
Ashokkumar Kothia
996,030₹243.7m0%no data
1.78%
Babu Kotadiya
213,409₹52.2m0%no data
1.69%
Gunjan Dhorajiya
202,773₹49.6m0%no data
1.44%
Trupti Patel
173,495₹42.4m0%no data
1.21%
Madras Mahadev
145,309₹35.5m0%no data
1.06%
Kailashben Bhandari
126,918₹31.1m0%no data
1%
Gunjan Kothia
120,000₹29.4m0%no data
0.85%
Susma Textiles LLP
102,391₹25.0m0%no data

Company Information

Shree Ganesh Remedies Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Shree Ganesh Remedies Limited
  • Ticker: 540737
  • Exchange: BSE
  • Founded: 1995
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ₹2.937b
  • Shares outstanding: 12.01m
  • Website: https://www.ganeshremedies.com

Number of Employees


Location

  • Shree Ganesh Remedies Limited
  • Plot No. 6011
  • G.I.D.C Estate
  • Ankleshwar
  • Gujarat
  • 393002
  • India


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
540737BSE (Mumbai Stock Exchange)YesEquity SharesININROct 2017

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/05 00:00
End of Day Share Price2022/10/04 00:00
Earnings2022/06/30
Annual Earnings2022/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.